Clinical Trials Logo

Closed Loop clinical trials

View clinical trials related to Closed Loop.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04042207 Completed - Clinical trials for Diabetes Mellitus, Type 1

Diabeloop for Highly Unstable Type 1 Diabetes

DBLHU
Start date: September 3, 2019
Phase: N/A
Study type: Interventional

Feasibility study, comparing experimental treatment (DBLHU closed-loop system) with reference treatment (Low Glucose Predictive Suspend system) in 7 patients going through a series of N-of-1 trials. Each N-of-1 trial consists in a prospectively planned, multiple crossover study in a single individual. Two blocks of two periods of four weeks each (closed loop or open loop) will be conducted. Within each block, the sequence closed loop-open loop or open loop-close loop is randomized. Outcomes will be analyzed on the third and fourth weeks of period. A remote monitoring system managed by specialized nurse on behalf of diabetologist, is provided in closed-loop session. An extension period of 48 weeks with the DBLHU System (closed-loop condition) will be performed at the end of the crossover study phase in real life conditions (without remote monitoring).

NCT ID: NCT03671915 Completed - Clinical trials for Diabetes Mellitus, Type 1

Diabeloop for Kids

DBL4K
Start date: May 6, 2019
Phase: N/A
Study type: Interventional

An open-label, three-center, randomized, two-session, 4 days inpatient and 6-week follow-up home study phase, crossover study comparing Diabeloop closed-loop (CL) system and sensor-augmented pump (SAP) therapy. The follow-up home study phase will be done only in French centers for a sub study. During this session, patient wearing the closed-loop system will benefit of a 24h/24, 7 d/7, remote monitoring follow-up by specialized nurses, under supervision of a diabetologist. A visualization of glucose CGM curves, insulin delivery, meal and physical activity announcements will be available online through secured website, and the system will send automated message in case of predetermined situations as persistent too high or too low Blood Glucose (BG). Custom settings will be possible by the nurses during the follow-up period.

NCT ID: NCT02987556 Completed - Clinical trials for Diabetes Mellitus, Type 1

Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7)

WP7
Start date: March 30, 2017
Phase: N/A
Study type: Interventional

The study will be conducted in crossover trial, with two 12-weeks periods separated by a Wash-out period of at least one month. According to randomization ,patients will be provided with either Diabeloop system or the usual system. Patients will be trained for the use of blood glucose meter, of external Insulin Pump and Diabeloop system. In both treatment periods, the same blood glucose meter will be used throughout the duration of the study. In two centers (Centre Hospitalier Sud-Francilien and Grenoble), a pre-study will be performed during four weeks to improve the efficacy of Diabeloop system with data collection, to test the manual settings by health care providers and patients and to check the good-working of the follow-up platform.

NCT ID: NCT02627911 Completed - Clinical trials for Diabetes Mellitus, Type 1

Diabeloop WP6.2 : Crossover Evaluation of Glycemic Control

WP6-2
Start date: November 2015
Phase: Phase 2
Study type: Interventional

The study will be conducted in crossover trial, with two 72-hour hospitalization separated by a period Wash-out of at least one week. Each hospitalization is a period of treatment. According to randomization, patients will be provided with either Diabeloop system or the usual system. In both treatment periods: - patients in a situation of sedentarity or physical activity, will be equipped with ActiGraph (measuring motricity) and a ActiHeart ( measuring heart rate) - meals and physical activities will be similar in both periods - the same blood glucose meter will be used throughout the duration of the study. - the capillary blood glucose will be performed : before bolus and 2 hours after a meal, before exercise, in case of hypo or hyper-glycemic episodes and when the patient and / or investigator deem it necessary.